Loading…
ALX Oncology Holdings Inc. is projected to rise to $2.37 by 2027, a +21% move from its current price of $1.96. ALXO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.89 | $1.96 | $2.04 | +0.09% |
| May 30 | $1.86 | $1.96 | $2.07 | +0.18% |
| May 31 | $1.84 | $1.97 | $2.10 | +0.28% |
| Jun 1 | $1.83 | $1.97 | $2.12 | +0.37% |
| Jun 2 | $1.81 | $1.97 | $2.14 | +0.46% |
| Jun 3 | $1.80 | $1.97 | $2.16 | +0.55% |
| Jun 4 | $1.79 | $1.97 | $2.18 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.79 | $1.97 | $2.18 | +0.65% |
| Week 2 | $1.73 | $1.99 | $2.28 | +1.30% |
| Week 3 | $1.69 | $2.00 | $2.37 | +1.95% |
| Week 4 | $1.65 | $2.01 | $2.45 | +2.61% |
| Week 5 | $1.63 | $2.02 | $2.52 | +3.27% |
| Week 6 | $1.60 | $2.04 | $2.59 | +3.94% |
| Week 7 | $1.58 | $2.05 | $2.66 | +4.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies for cancer patients in the United States. Its lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic developed as a combination therapy with other anti-cancer agents, including ASPEN-06, in a phase 2 study for treating Gastric/GEJ cancer.
The company maintains collaboration agreements for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; a HER2 ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma.
The company has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALXO Oncology Holdings Inc., trading under the symbol ALXO, currently trades at $1.98. It has a market capitalization of $266.43M and ranks 3624 in market size. The stock operates within the Healthcare category.
A major floor 40.3% below — a decisive break under it would weaken the trend.
The nearest floor, 19.4% below — buyers have tended to step in here.
The nearest ceiling, 6.6% above — a clean break opens room to run.
A major ceiling 32.7% above — clearing it would confirm fresh momentum.
Key ALXO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALXO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.97 | Sell | $1.97 | Sell |
| MA 10 | $1.99 | Sell | $1.97 | Sell |
| MA 20 | $1.94 | Buy | $1.94 | Buy |
| MA 50 | $1.90 | Buy | $1.91 | Buy |
| MA 100 | $1.88 | Buy | $1.83 | Buy |
| MA 200 | $1.63 | Buy | $1.74 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.41 | Neutral |
| Stoch RSI (14) | 21.08 | Neutral |
| CCI (20) | 11.83 | Neutral |
| Williams %R (14) | -57.14 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -5.77 | Sell |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 42.86 | Neutral |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | 0.14 | Buy |
| Ultimate (7,14,28) | 37.93 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 1.95 | Buy |
| ADX (14) | 12.96 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture shows a BULLISH sentiment with RSI14 at 50. The 50-day simple moving average is $1.90 and the 200-day simple moving average is $1.62, providing a framework of near-term support and resistance. Support is noted at $1.58 and resistance at $2.09, with a 30-day price range between $1.53 and $2.56.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.08 | $1.96 | $2.75 | 0% | Neutral | |
| $1.81 | $2.37 | $3.31 | +21% | Bullish | |
| $1.85 | $2.51 | $3.68 | +28% | Bullish | |
| $1.88 | $2.63 | $3.99 | +34% | Bullish | |
| $1.76 | $2.54 | $3.97 | +30% | Bullish | |
| $2.03 | $3.01 | $4.84 | +54% | Bullish | |
| $2.59 | $3.94 | $6.48 | +101% | Bullish | |
| $2.71 | $4.21 | $7.07 | +115% | Bullish | |
| $2.94 | $4.68 | $8.01 | +139% | Bullish | |
| $2.97 | $4.83 | $8.43 | +147% | Bullish | |
| $4.55 | $8.19 | $15.40 | +318% | Bullish | |
| $5.54 | $12.01 | $25.14 | +513% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.08 | $1.96 | $2.31 | +0.00% |
| June 2026 | $1.70 | $2.01 | $2.44 | +2.46% |
| July 2026 | $1.78 | $2.13 | $2.64 | +6.14% |
| August 2026 | $1.79 | $2.16 | $2.71 | +1.21% |
| September 2026 | $1.72 | $2.09 | $2.66 | -2.94% |
| October 2026 | $1.72 | $2.11 | $2.71 | +0.89% |
| November 2026 | $1.75 | $2.16 | $2.80 | +2.34% |
| December 2026 | $1.70 | $2.11 | $2.75 | -2.40% |
Click any year to see its month-by-month ALXO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALXO to range from $1.08 to $2.75 through 2026. The $1.96 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALXO price prediction for 2027 points to an average of $2.37 (low $1.81, high $3.31) — a potential gain of +21% on today's $1.96. Momentum favours further upside here.
In 2028, ALXO is projected to trade between $1.85 and $3.68, averaging $2.51 — a potential gain of +28% from today's $1.96. That is up +6% on the projected 2027 average. Buyers look set to stay in control over this stretch.
ALX Oncology Holdings Inc.'s 2029 outlook centres on $2.63, within a $1.88 to $3.99 range. That is up +5% on the projected 2028 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2030, ALXO could reach as high as $3.97, with a base case around $2.54 and support toward $1.76 — roughly +30% from $1.96. Buyers look set to stay in control over this stretch.
Expect ALXO to range from $2.03 to $4.84 through 2031. The $3.01 average target implies a +54% move from current prices. That is up +19% on the projected 2030 average. Momentum favours further upside here.
The ALXO price prediction for 2032 points to an average of $3.94 (low $2.59, high $6.48) — a potential gain of +101% on today's $1.96. Buyers look set to stay in control over this stretch.
In 2033, ALXO is projected to trade between $2.71 and $7.07, averaging $4.21 — a potential gain of +115% from today's $1.96. That is up +7% on the projected 2032 average. Momentum favours further upside here.
ALX Oncology Holdings Inc.'s 2034 outlook centres on $4.68, within a $2.94 to $8.01 range. That is up +11% on the projected 2033 average. That marks a +139% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALXO could reach as high as $8.43, with a base case around $4.83 and support toward $2.97 — roughly +147% from $1.96. Momentum favours further upside here.
Expect ALXO to range from $4.55 to $15.40 through 2040. The $8.19 average target implies a +318% move from current prices. That is up +70% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALXO price prediction for 2050 points to an average of $12.01 (low $5.54, high $25.14) — a potential gain of +513% on today's $1.96. Momentum favours further upside here.
Investing $1,000 in ALXO today (≈ 510.204082 ALXO) could be worth
$6,126.56
+$5,126.56 (+513%) by 2050 · US Dollar
Based on the average projected ALXO price of $12.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALXOwould be worth at today's price.
$1,000 invested in ALXO on May 27, 2025 (≈ 2,232.142788 ALXO) would be worth
$4,375
+$3,375 (+337.5%) today · 4.37× · US Dollar
Based on a ALXO entry price of $0.448 vs. today's $1.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.99 | $984.92 | -1.5% |
| 1 month ago | $1.59 | $1,232.7 | +23.3% |
| 3 months ago | $2.35 | $834.04 | -16.6% |
| 6 months ago | $1.37 | $1,430.66 | +43.1% |
| 1 year ago | $0.448 | $4,375 | +337.5% |
| All time (5.0y) ago | $56.33 | $34.79 | -96.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALXO forecast.
Our base-case forecast reaches $3.90 around 2032.
Implied market cap at $3.90: $524.8M
The multi-year forecast outlines a path of gradual appreciation with bullish sentiment becoming more evident over time. In 2030 the average price is projected at $2.38 with an ROI of 20.3, while 2040 shows an average of $7.00 with an ROI of 253.3, and 2050 projects an average of $9.79 with an ROI of 394.3. This trajectory suggests meaningful upside from the current level, supported by higher expected medians in later years and expanding downside protection.
As with all forecasts, these are estimates and not guarantees, and actual results may vary.
Tap a question to reveal the answer.
The forecast for 2030 lists an avg of $2.38 with a min of $1.63, a max of $3.77, and an ROI of 20.3. The sentiment is BULLISH.
Forecasts show a bullish sentiment in later years with an average price rising to $9.79 by 2050 and a max of $20.95, though the 2026 path begins at an average of $1.98 with an ROI of 0. This illustrates potential upside alongside early-year uncertainty.
Yes. The year-by-year forecast shows a max of $5.85 in 2032, with higher upside in 2040 ($13.40 max) and 2050 ($20.95 max). The average prices in those years also reflect continued growth.
The 30-day range is $1.53 to $2.56.
ALX Oncology Holdings Inc. Community Discussion
0Share your ALX Oncology Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.